Results of Zibotentan Phase III trial in castration resistant prostate cancer
Posted: 27 September 2010 | | No comments yet
AstraZeneca announced that a study evaluating zibotentan for the treatment of men with metastatic CRPC did not show improvement in the primary endpoint of overall survival…
AstraZeneca announced that a study evaluating zibotentan for the treatment of men with metastatic CRPC did not show improvement in the primary endpoint of overall survival...
AstraZeneca today announced that a study evaluating zibotentan for the treatment of men with metastatic castration resistant prostate cancer (CRPC) did not show a significant improvement in the primary endpoint of overall survival (OS).
Study 14 was a randomised, placebo controlled phase III study which evaluated zibotentan 10mg added to standard of care treatment in 594 patients with metastatic CRPC. The safety and tolerability profile of zibotentan in this trial was in line with previous studies.
Based on this study result, AstraZeneca plans no regulatory submissions for zibotentan at this time. The zibotentan ENTHUSE trial programme includes two other ongoing studies with zibotentan in different CRPC settings. The full results of study 14 will be published in 2011.
